Date: 2022-01-10

Type of information: Plant acquisition

Compound: Cramlington Site in Newcastle (UK)

Company: Pharmaron Beijing (China) Recipharm (Sweden)

Therapeutic area: Technology - Services

Type agreement: plant acquisition

Action mechanism:



Pharmaron Beijing announced = that it has acquired Aesica Pharmaceuticals (“The Cramlington Site”) from Recipharm group. The Cramlington Site in Newcastle, United Kingdom, has an established history of cGMP manufacturing services for an array of Active Pharmaceutical Ingredients (API), ranging from pilot scale to commercial metric ton scale. The Cramlington Site has more than 100 cubic meter reactor commercial capacity and has been inspected and approved by the MHRA, FDA and other regulatory authorities.
This acquisition expands Pharmaron's world-class chemistry and manufacturing services, which is an important component of its fully integrated platform. The synergistic integration of the Cramlington Site with Pharmaron’s existing service capabilities of discovery, process development and early-stage cGMP API manufacturing at Hoddesdon will enable a complete end-to-end chemistry and manufacturing service offering in the United Kingdom. This addition further strengthens Pharmaron’s global service network to provide customized solutions to meet our partners’ geographic and strategic needs. Goetzpartners securities acted as exclusive financial advisor to Pharmaron, and O’Melveny acted as legal advisor. Results Healthcare acted as exclusive financial advisor to Recipharm and Addleshaw Goddard acted as legal advisor.

Financial terms:

Latest news:

Is general: Yes